U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT03394950) titled 'Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke' on Jan. 3, 2018.
Brief Summary: Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of morbidity, mortality and disability. A large number of studies have confirmed that the thrombolytic therapy can effectively open blood vessels and improve the functional prognosis of acute ischemic stroke. Therefore, all guidelines recommend giving thrombolysis treatment to acute ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients receiving thrombolysis will have good prognosis, while a la...